Blog

Francisco Esteva: Do all Breast Cancer Patients need Chemotherapy?

Francisco Esteva/LinkedIn

May 29, 2025, 10:44

Francisco Esteva: Do all Breast Cancer Patients need Chemotherapy?

Francisco Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and a Professor of Medicine at the Zucker School of Medicine, shared a post on LinkedIn:

“Do all breast cancer patients need chemotherapy?

Not always—and multi-gene tests are changing the game.

For many people with hormone receptor-positive, HER2-negative early-stage breast cancer, the decision to use chemotherapy isn’t straightforward. That’s where genomic assays like Oncotype DX, MammaPrint, and others come in.

These tests analyze multiple genes in the tumor to estimate the risk of recurrence.

They help doctors—and patients—decide whether adding chemo to hormone therapy offers real benefit.

This is personalized medicine in action.

It reduces unnecessary treatment and focuses care where it’s truly needed.

Curious how it works and who qualifies?

Watch the video attached. It could change how we think about cancer treatment decisions.”

Francisco Esteva emphasized the value of genomic tests such as Oncotype DX and MammaPrint in guiding chemotherapy decisions for early-stage hormone receptor-positive, HER2-negative breast cancer. These tools support personalized treatment by estimating recurrence risk and avoiding unnecessary chemotherapy.

More posts featuring Francisco Esteva.

Breast Cancer cancer chemotherapy fight against cancer Francisco Esteva Global fight against cancer HER2 Lenox Hill Hospital MammaPrint OncoDaily Oncology Oncotype DX Zucker School of Medicine

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action